tiprankstipranks
West Pharmaceutical Services, Inc. (CH:WPS)
NYSE:WPS
Switzerland Market
WPS
West Pharmaceutical Services
RESEARCH TOOLSreports

West Pharmaceutical Services (WPS) Stock Forecast & Price Target

1 Followers
See the Price Targets and Ratings of:

WPS Analyst Ratings

Strong Buy
8Ratings
Strong Buy
7 Buy
1 Hold
0 Sell
Based on 8 analysts giving stock ratings to
West
Pharmaceutical Services
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

WPS Stock 12 Month Forecast

Average Price Target

$297.41
Based on 8 Wall Street analysts offering 12 month price targets for West Pharmaceutical Services in the last 3 months. The average price target is $297.41 with a high forecast of $318.93 and a low forecast of $259.13. The average price target represents a ― change from the last price of ―.
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
Highest Price Target$318.93Average Price Target$297.41Lowest Price Target$259.13
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Barclays Analyst forecast on CH:WPS
Luke Sergott
Barclays
Barclays
CHF247.17→CHF318.93
Buy
―
Upgraded
06/09/26
West Pharmaceutical upgraded to Overweight from Equal Weight at BarclaysWest Pharmaceutical upgraded to Overweight from Equal Weight at Barclays
Bank of America Securities Analyst forecast on CH:WPS
Michael Ryskin
Bank of America Securities
Bank of America Securities
―
Buy
―
Reiterated
06/02/26
Analysts Offer Insights on Healthcare Companies: West Pharmaceutical Services (NYSE: WST) and MAIA Biotechnology, Inc. (NYSE MKT: MAIA)
Wolfe Research Analyst forecast on CH:WPS
Michael Polark
Wolfe Research
Wolfe Research
CHF299
Buy
―
Assigned
06/01/26
West Pharmaceutical assumed at Outperform from Peer Perform at Wolfe ResearchWest Pharmaceutical assumed at Outperform from Peer Perform at Wolfe Research
Morgan Stanley Analyst forecast on CH:WPS
Kallum Titchmarsh
Morgan Stanley
Morgan Stanley
CHF251.16→CHF259.13
Hold
―
Assigned
05/29/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: PepGen Inc. (NASDAQ: PEPG) and West Pharmaceutical Services (NYSE: WST)
William Blair Analyst forecast on CH:WPS
Matt Larew
William Blair
William Blair
―
Buy
―
Reiterated
05/20/26
Analysts Are Bullish on Top Healthcare Stocks: EBR Systems, Inc. Shs Chess Depository Interests Repr 1 Sh (AU:EBR), West Pharmaceutical Services (WST)
Citi Analyst forecast on CH:WPS
Patrick B Donnelly
Citi
Citi
CHF299→CHF318.93
Buy
―
Reiterated
04/24/26
West Pharmaceutical price target raised to $400 from $375 at CitiWest Pharmaceutical price target raised to $400 from $375 at Citi
TD Cowen Analyst forecast on CH:WPS
Brendan Smith
TD Cowen
TD Cowen
CHF279.07→CHF291.03
Buy
―
Assigned
04/23/26
West Pharmaceutical Services (WST) Gets a Buy from TD Cowen
Evercore ISI Analyst forecast on CH:WPS
Vijay Kumar
Evercore ISI
Evercore ISI
―
Buy
―
Reiterated
04/23/26
Analysts Offer Insights on Healthcare Companies: LB Pharmaceuticals, Inc. (NASDAQ: LBRX) and West Pharmaceutical Services (NYSE: WST)
RBC Capital Analyst forecast on CH:WPS
Dan Leonard
RBC Capital
RBC Capital
CHF283.05→CHF271.09
Buy
―
Reiterated
02/13/26
West Pharmaceutical price target lowered to $340 from $355 at UBSWest Pharmaceutical price target lowered to $340 from $355 at UBS
Deutsche Bank Analyst forecast on CH:WPS
Justin Bowers
Deutsche Bank
Deutsche Bank
CHF247.17→CHF251.16
Buy
―
Reiterated
02/13/26
West Pharmaceutical price target raised to $315 from $310 at Deutsche BankWest Pharmaceutical price target raised to $315 from $310 at Deutsche Bank
Jefferies Analyst forecast on CH:WPS
David Windley
Jefferies
Jefferies
CHF291.03→CHF235.21
Buy
―
Reiterated
02/10/26
Jefferies Keeps Their Buy Rating on West Pharmaceutical Services (WST)
DBS Analyst forecast on CH:WPS
Nico Chen
DBS
DBS
CHF255.15
Buy
―
Reiterated
01/28/26
DBS Sticks to Their Buy Rating for West Pharmaceutical Services (WST)
Nephron Analyst forecast on CH:WPS
Thomas DeBourcy
Nephron
Nephron
CHF292.62
Buy
―
Upgraded
12/11/25
West Pharmaceutical upgraded to Buy from Hold at Nephron ResearchWest Pharmaceutical upgraded to Buy from Hold at Nephron Research
KeyBanc Analyst forecast on CH:WPS
Paul Knight
KeyBanc
KeyBanc
CHF259.13→CHF279.07
Buy
―
Reiterated
10/24/25
KeyBanc Keeps Their Buy Rating on West Pharmaceutical Services (WST)
Rothschild & Co Redburn Analyst forecast on CH:WPS
Jamie Clark
Rothschild & Co Redburn
Rothschild & Co Redburn
CHF247.97
Buy
―
Initiated
09/15/25
West Pharmaceutical Services (WST) Has a New Rating from Redburn Atlantic
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Barclays Analyst forecast on CH:WPS
Luke Sergott
Barclays
Barclays
CHF247.17→CHF318.93
Buy
―
Upgraded
06/09/26
West Pharmaceutical upgraded to Overweight from Equal Weight at BarclaysWest Pharmaceutical upgraded to Overweight from Equal Weight at Barclays
Bank of America Securities Analyst forecast on CH:WPS
Michael Ryskin
Bank of America Securities
Bank of America Securities
―
Buy
―
Reiterated
06/02/26
Analysts Offer Insights on Healthcare Companies: West Pharmaceutical Services (NYSE: WST) and MAIA Biotechnology, Inc. (NYSE MKT: MAIA)
Wolfe Research Analyst forecast on CH:WPS
Michael Polark
Wolfe Research
Wolfe Research
CHF299
Buy
―
Assigned
06/01/26
West Pharmaceutical assumed at Outperform from Peer Perform at Wolfe ResearchWest Pharmaceutical assumed at Outperform from Peer Perform at Wolfe Research
Morgan Stanley Analyst forecast on CH:WPS
Kallum Titchmarsh
Morgan Stanley
Morgan Stanley
CHF251.16→CHF259.13
Hold
―
Assigned
05/29/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: PepGen Inc. (NASDAQ: PEPG) and West Pharmaceutical Services (NYSE: WST)
William Blair Analyst forecast on CH:WPS
Matt Larew
William Blair
William Blair
―
Buy
―
Reiterated
05/20/26
Analysts Are Bullish on Top Healthcare Stocks: EBR Systems, Inc. Shs Chess Depository Interests Repr 1 Sh (AU:EBR), West Pharmaceutical Services (WST)
Citi Analyst forecast on CH:WPS
Patrick B Donnelly
Citi
Citi
CHF299→CHF318.93
Buy
―
Reiterated
04/24/26
West Pharmaceutical price target raised to $400 from $375 at CitiWest Pharmaceutical price target raised to $400 from $375 at Citi
TD Cowen Analyst forecast on CH:WPS
Brendan Smith
TD Cowen
TD Cowen
CHF279.07→CHF291.03
Buy
―
Assigned
04/23/26
West Pharmaceutical Services (WST) Gets a Buy from TD Cowen
Evercore ISI Analyst forecast on CH:WPS
Vijay Kumar
Evercore ISI
Evercore ISI
―
Buy
―
Reiterated
04/23/26
Analysts Offer Insights on Healthcare Companies: LB Pharmaceuticals, Inc. (NASDAQ: LBRX) and West Pharmaceutical Services (NYSE: WST)
RBC Capital Analyst forecast on CH:WPS
Dan Leonard
RBC Capital
RBC Capital
CHF283.05→CHF271.09
Buy
―
Reiterated
02/13/26
West Pharmaceutical price target lowered to $340 from $355 at UBSWest Pharmaceutical price target lowered to $340 from $355 at UBS
Deutsche Bank Analyst forecast on CH:WPS
Justin Bowers
Deutsche Bank
Deutsche Bank
CHF247.17→CHF251.16
Buy
―
Reiterated
02/13/26
West Pharmaceutical price target raised to $315 from $310 at Deutsche BankWest Pharmaceutical price target raised to $315 from $310 at Deutsche Bank
Jefferies Analyst forecast on CH:WPS
David Windley
Jefferies
Jefferies
CHF291.03→CHF235.21
Buy
―
Reiterated
02/10/26
Jefferies Keeps Their Buy Rating on West Pharmaceutical Services (WST)
DBS Analyst forecast on CH:WPS
Nico Chen
DBS
DBS
CHF255.15
Buy
―
Reiterated
01/28/26
DBS Sticks to Their Buy Rating for West Pharmaceutical Services (WST)
Nephron Analyst forecast on CH:WPS
Thomas DeBourcy
Nephron
Nephron
CHF292.62
Buy
―
Upgraded
12/11/25
West Pharmaceutical upgraded to Buy from Hold at Nephron ResearchWest Pharmaceutical upgraded to Buy from Hold at Nephron Research
KeyBanc Analyst forecast on CH:WPS
Paul Knight
KeyBanc
KeyBanc
CHF259.13→CHF279.07
Buy
―
Reiterated
10/24/25
KeyBanc Keeps Their Buy Rating on West Pharmaceutical Services (WST)
Rothschild & Co Redburn Analyst forecast on CH:WPS
Jamie Clark
Rothschild & Co Redburn
Rothschild & Co Redburn
CHF247.97
Buy
―
Initiated
09/15/25
West Pharmaceutical Services (WST) Has a New Rating from Redburn Atlantic
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
TRAXFirst Tracks Biotherapeutics Inc
EVMNEvommune, Inc.
MPLTMapLight Therapeutics, Inc.
MAZEMaze Therapeutics, Inc.
AAPGAscentage Pharma Group International Unsponsored ADR
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering West Pharmaceutical Services

3 Months
Matt LarewWilliam Blair
Success Rate
7/9 ratings generated profit
78%
Average Return
+12.60%
Copying Matt Larew's trades and holding each position for 3 Months would result in 77.78% of your transactions generating a profit, with an average return of +12.60% per trade.
1 Year
Matt LarewWilliam Blair
Success Rate
8/9 ratings generated profit
89%
Average Return
+20.38%
Copying Matt Larew's trades and holding each position for 1 Year would result in 88.89% of your transactions generating a profit, with an average return of +20.38% per trade.
2 Years
Matt LarewWilliam Blair
Success Rate
8/9 ratings generated profit
89%
Average Return
+20.42%
Copying Matt Larew's trades and holding each position for 2 Years would result in 88.89% of your transactions generating a profit, with an average return of +20.42% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

WPS Analyst Recommendation Trends

Rating
Feb 26
Mar 26
Apr 26
May 26
Jun 26
Strong Buy
1
2
1
1
0
Buy
15
13
12
9
11
Hold
5
3
6
7
8
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
21
18
19
17
19
In the current month, WPS has received 11 Buy Ratings, 8 Hold Ratings, and 0 Sell Ratings. WPS average Analyst price target in the past 3 months is 297.41.
Each month's total comprises the sum of three months' worth of ratings.

WPS Financial Forecast

WPS Earnings Forecast

Next quarter’s earnings estimate for WPS is $1.66 with a range of $1.63 to $1.67. The previous quarter’s EPS was $1.70. WPS beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year WPS has Performed in-line its overall industry.
Next quarter’s earnings estimate for WPS is $1.66 with a range of $1.63 to $1.67. The previous quarter’s EPS was $1.70. WPS beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year WPS has Performed in-line its overall industry.

WPS Sales Forecast

Next quarter’s sales forecast for WPS is $668.42M with a range of $661.79M to $677.52M. The previous quarter’s sales results were $673.43M. WPS beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year WPS has Performed in-line its overall industry.
Next quarter’s sales forecast for WPS is $668.42M with a range of $661.79M to $677.52M. The previous quarter’s sales results were $673.43M. WPS beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year WPS has Performed in-line its overall industry.

WPS Stock Forecast FAQ

What is CH:WPS’s average 12-month price target, according to analysts?
Based on analyst ratings, West Pharmaceutical Services, Inc.’s 12-month average price target is 297.41.
    What is CH:WPS’s upside potential, based on the analysts’ average price target?
    Currently there's no upside potential for CH:WPS, based on the analysts’ average price target.
    Can I see which stocks the top-ranking analysts are rating?
    Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
      How can I follow the stock ratings of top Wall Street analysts?
      Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
        Is West Pharmaceutical Services, Inc. a Buy, Sell or Hold?
        West Pharmaceutical Services, Inc. has a consensus rating of Strong Buy, which is based on 7 buy ratings, 1 hold ratings and 0 sell ratings.
          What is West Pharmaceutical Services, Inc.’s share price target?
          The average share price target for West Pharmaceutical Services, Inc. is 297.41. This is based on 8 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
          The highest analyst share price target is $318.93 ,and the lowest forecast is $259.13. The average share price target represents N/A Increase from the current price of N/A.
            What do analysts say about West Pharmaceutical Services, Inc.?
            West Pharmaceutical Services, Inc.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 8 Wall Streets Analysts.
              How can I buy shares of West Pharmaceutical Services, Inc.?
              To buy shares of CH:WPS, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.